Senores Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹114Cr
- +11.8% YoY
- +10.7% QoQ
- Net profit
- ₹18Cr
- +28.6% YoY
- +12.5% QoQ
- Margin
- 17%
- −5 pp YoY
- −8 pp QoQ
Guidance rank: #13 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets. The company targets over 50% top-line growth in FY26 compared to FY25.
From Senores Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets.
- Approximately 31 new ANDA product launches in the regulated market are expected in FY26.
- Around 23 CDMO-CMO products are planned for commercialization in the current financial year.
- Expansion in oral solids production capacity with two existing and two more lines being operational soon.
- Emerging market product portfolio aims to grow to over 650 registered products by FY27.
- Emerging market business margins expected to improve significantly, moving towards 15-16% EBITDA in 2 years.
- PAT guidance for FY26 is a 100% increase compared to FY25, indicating strong profitability growth.
- Growth driven by product mix changes, higher realizations, and strategic acquisitions.
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for FY26 is planned at INR 250 crores (Page 15).
- Oral solids capacity expansion is ongoing with the 3rd line being installed and a 4th line planned to meet increased demand (Page 9).
- New API facility (100-120 MTPA capacity) has commenced production; FDA trigger expected by Q2 2026 to support backward integration for US business (Pages 14-15).
- The API facility primarily serves in-house needs with some external sales; it is positioned strategically rather than as a separate business vertical (Pages 14-15).
- Focus is on changing product mix to improve realization and EBITDA margins (Page 10).
2 more points from Senores Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Senores Pharmaceuticals has a strong order book and good visibility in its CDMO-CMO segment.
- The company continues to see steady traction and scaling up in the CDMO-CMO segment.
- The portfolio now includes about 22 commercial products in CDMO-CMO with around 69 products in the pipeline at various stages.
- Many of these pipeline products are expected to be commercialized in the current fiscal year.
- The company has a solid pipeline with plans to launch 31 ANDA (Abbreviated New Drug Applications) products in the regulated market and 23 CDMO-CMO products in the current financial year.
2 more points from Senores Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Senores Pharmaceuticals Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 114 | 102 | +11.8% | 103 | +10.7% |
| Operating profit (EBITDA) | 19 | 22 | -13.6% | 26 | -26.9% |
| Operating margin | 17% | 22% | -5 pp | 25% | -8 pp |
| Profit before tax | 21 | 18 | +16.7% | 20 | +5% |
| Net profit (PAT) | 18 | 14 | +28.6% | 16 | +12.5% |
| EPS (₹) | 3.87 | 5.23 | -26% | 3.73 | +3.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q4 FY25 results?
The company targets over 50% top-line growth for FY26, driven by both regulated and emerging markets. The company targets over 50% top-line growth in FY26 compared to FY25.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
Capex for FY26 is planned at INR 250 crores (Page 15).
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
